These findings align with the increased CD44 expression confirmed by Western blot analysis (Fig. 4a, c), demonstrating that both CRAd-synNotch and ADX730 treatments are capable of inducing elevated levels of CD44-ECD as a part of synNotch protein on the surface of tumor cells. Here, CD44 is linked to neoplasm.